化合物 Barasertib|T2602|TargetMol

價(jià)格	￥339	￥498	￥698
包裝	2mg	5mg	10mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 Barasertib	英文名稱:Barasertib-HQPA
CAS:722544-51-6	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.29%	產(chǎn)品類別: 抑制劑
貨號(hào): T2602

Product Introduction

Bioactivity

名稱	Barasertib-HQPA
描述	Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor (IC50: 0.37 nM) and demonstrates ~3,700-fold greater selectivity than Aurora A.
細(xì)胞實(shí)驗(yàn)	LNCaP cells were cultured in RPMI 1640 medium supplemented with 10 % fetal bovine serum, in 5 % CO2 at 37 °C. The cells were treated with 5, 10, 50, 100, and 500 nM of AZD1152-HQPA for 48 h. After 48-h treatment with AZD1152-HQPA, cells were further incubated with 100 μl of MTT (0.5 mg/ml) at 37 °C for 2 h. Precipitated formazan was solubilized with 100 μl of DMSO, and the optical densitometry was measured at a wavelength of570 nm. Cell treated with 0.1 % DMSO was defined as the control group [2].
動(dòng)物實(shí)驗(yàn)	Female immune-deficient BALB/c nude mice at 4 weeks of age were maintained in pathogen-free conditions with irradiated chow. Animals were bilaterally, subcutaneously injected with 2 × 10^6 MOLM13 cells/tumor in 0.1 mL Matrigel. When MOLM13 cells formed palpable tumors, mice were divided randomly into control (n=5) and treatment groups (n=5), and treatment was begun. AZD1152 (5 or 25 mg/kg) with or without vincristine (0.2 mg/kg) was given to mice by intraperitoneal injection 4 times a week or every another day, respectively. Daunorubicin (1 mg/kg) was given to mice by intraperitoneal injection 6 times during 2 weeks of treatment either alone or in combination with AZD1152 (5 mg/kg). The dose of these agents was determined by our preliminary studies (data not shown). Control diluent was given to the untreated control mice. Body weight and tumors were measured twice a week. Tumor sizes were calculated by the formula: a × b × c, where "a" is the length, "b" is the width, and "c" is the height in millimeters. At the end of the experiment, animals were killed by CO2 asphyxiation and tumor weights were measured after their careful resection. Tumor tissue was collected for analysis [1].
體外活性	Barasertib抑制了急性髓性白血?。ˋML）系列（HL-60, NB4, MOLM13）、急性淋巴性白血病（ALL）系列（PALL-2）、雙表型白血?。∕V4-11）、急性嗜酸性白血?。‥OL-1）以及慢性髓性白血病爆發(fā)期K562細(xì)胞的增殖，其半抑制濃度（IC50）范圍為3 nM至40 nM [1]。Barasertib-HQPA處理導(dǎo)致LNCaP細(xì)胞系的存活能力缺陷、多倍體以及細(xì)胞死亡，并降低了AR表達(dá) [2]。
體內(nèi)活性	Barasertib對(duì)AML系列(HL-60, NB4, MOLM13)、ALL系列(PALL-2)、雙表型白血病(MV4-11)、急性嗜酸性白血病(EOL-1)以及慢性髓性白血病危重期K562細(xì)胞的增殖抑制作用顯著，IC50值介于3 nM至40 nM之間[1]。Barasertib-HQPA處理導(dǎo)致LNCaP細(xì)胞系存活能力受損、多倍體形成及細(xì)胞死亡。此外，Barasertib-HQPA治療降低了AR表達(dá)[2]。Barasertib強(qiáng)力抑制了免疫缺陷小鼠中人類結(jié)腸、肺和血液腫瘤異種移植物的生長(zhǎng)。在用Barasertib靜脈治療攜帶SW620結(jié)直腸腫瘤的無(wú)胸腺大鼠中，首先觀察到組蛋白H3磷酸化的暫時(shí)抑制，隨后細(xì)胞中4N DNA含量比對(duì)照組高出2.4倍，繼而多倍體細(xì)胞比例增加[3]。
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	Ethanol : 3 mg/mL (5.91 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 94 mg/mL (185.2 mM)
關(guān)鍵字	colon \| Inhibitor \| Barasertib-HQPA \| Apoptosis \| Aurora Kinase \| BarasertibHQPA \| AZD 2811 \| cancer \| INH 34 \| AZD1152-HQPA\|AZD 2811 \| leukemia \| breast \| inhibit \| AZD1152-HQPA\|AZD-2811 \| lung \| INH-34 \| AZD-2811 \| INH34 \| Barasertib HQPA
相關(guān)產(chǎn)品	L-Glutamic acid \| Metronidazole \| 5-Fluorouracil \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Tributyrin \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Salicylic acid \| Sodium 4-phenylbutyrate
相關(guān)庫(kù)	抑制劑庫(kù) \| 經(jīng)典已知活性庫(kù) \| 抗癌活性化合物庫(kù) \| 已知活性化合物庫(kù) \| 激酶抑制劑庫(kù) \| 抗衰老化合物庫(kù) \| 高選擇性抑制劑庫(kù) \| 藥物功能重定位化合物庫(kù) \| 抗癌臨床化合物庫(kù) \| 抗癌藥物庫(kù)

關(guān)鍵字： Barasertib|||AZD2811|||AZD1152-HQPA|AZD2811|||AZD1152-HQPA|||1H-Pyrazole-3-acetamide|TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū)，已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù)，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.265100萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 3年

公司成立：12年
注冊(cè)資本：566.265100萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑、藥物篩選化合物庫(kù)、藥物篩選等
公司地址：靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 GNE-9822|T31982|TargetMol

￥3770

化合物 THP-PEG4-Pyrrolidine(N-Me)-CH2OH|T18847|TargetMol

￥387

a-葡糖-a-葡糖苷|T20839|TargetMol

￥993